University of California San Francisco
Give to UCSFBreast cancer is the second leading cause of cancer deaths in the U.S. and worldwide, pointing to the continuing need to improve treatment strategies and therapies that better patient survival and
Mekhail Anwar leads a multi-institution $15 million grant from ARPA-H to develop imaging technology to improve cancer surgery.
Oncology specialists from around the world came together for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest developments in cancer care, research,
Energy expended for hospital and clinic electricity, climate control and ventilation is by far the biggest source of greenhouse gas emissions in radiotherapy, a treatment used in more than half of cancer cases.
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s
Cell biologist and engineer Matthew Kutys, PhD, and his team harness organoids – living tissues derived from patient tumors – to study how cancer spreads.
UCSF researchers found that regular screening is not always sufficient to prevent an advanced breast cancer diagnosis.
Breast cancer was the second most commonly diagnosed cancer in women, after skin cancer – accounting for 31% of all new female cancer diagnoses in 2022. Yet, determining who is most at risk of breast
Laura Esserman discusses breast cancer risk factors, progress in the field and the importance of tailoring treatment for women with low-risk cancer while also identifying women at high risk of invasive cancer.
Researchers have found that people who developed breast, ovary, skin and uterine cancers have significantly higher levels of endocrine-disrupting chemicals in their bodies.
Engineered immune cells. Supercharged scans. Drug implants. Gene manipulators. Blood biopsies. Read how these breakthroughs are transforming cancer care.
Laws in many states require notifying women if they have dense breasts, a risk factor for breast cancer. But density shouldn’t be the only factor in determining whether supplemental screening is
Oncology specialists from around the globe will gather for the American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest cancer therapies, technologies, research and education.
Leading cancer researchers from UCSF will present at this year’s annual meeting of the American Association for Cancer Research (AACR) conference, held April 14-19, 2023, in Orlando.
A new digital tool helps to calculate breast cancer risk for those who may develop advanced cancer that goes undiagnosed despite regular screenings.
Sick leave coverage expansion were associated with higher rates of mammography screening and colorectal screening, potentially leading to better health outcomes.
The WISDOM 2.0 study aims to transform breast cancer screening by using a personalized approach and will expand to women as young as 30.
UCSF breast cancer experts will present new research and clinical findings at the annual San Antonio Breast Cancer Symposium, the largest and most prestigious breast cancer conference.
A new UCSF study reports for the first time that significant hearing issues often occur among adult survivors of the most common forms of cancer.
For many women, breast cancer screening with a three-dimensional imaging technique called digital breast tomosynthesis (DBT) may not offer advantages over digital mammography, but for some it may reduce the chance of an advanced cancer diagnosis, according to a new JAMA study.
UCSF research scientists and statisticians have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.
The latest advances in cancer care and research will be showcased at the annual American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer meeting.